A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma

Annals of the Academy of Medicine Singapore

Volumn 27, Issue 5, 1998, Pages 650-656

  Shimizu, Y ^a   Umezawa, S ^b   Hasumi, K ^b  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b NONE

Author keywords

Chemotherapy; Diarrhoea; Neutropenia; Platinum resistance

Indexed keywords

IRINOTECAN; MITOMYCIN C;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUCINOUS CARCINOMA; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0032436603     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Markman M, Hakes T, Reichman B, Lewis J L, Rubin S, Jones W, et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistance disease. J Clin Oncol 1 992; 10:243-8.
2. Creemers G J, Bolis G, Gore M, Scarfone G, Lace A J, Guastalla J P, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996; 14:3056-61.
3. Sarosy G, Kohl E, Stone D A. Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992; 10:1165-70.
4. Einzig A, Wiernik P, Sasloff J. Phase II study and long term follow up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992; 10:1748-53.
5. Trimble E L, Adams J D, Vena D, Hawkins M J, Friedman M A, Fisherman J S, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993; 11:2405-10.
6. Kohn E C, Sarosy G. Bicher A, Link C, Christian M, Steinberg S M, et al. Dose-intense Taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994; 86:18-24.
7. Thigpen J T, Blessing J A, Ball H, Humme S J, Barrett R J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994; 12:1748-53.
8. Mayerhofer K, Kucera E, Zeisler H, Speiser P, Reinthaller A, Sevelda P. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy. Gynecol Oncol 1997; 64:109-13.
9. Francis P, Schneider J, Hann L, Balmaceda C, Barakat R, Phillips M, et al. Phase II trial of doce-taxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994; 12:2301-8.
10. Piccart M J, Gore M, Ten Bokkel Huinink W, Van Oosterom A, Verweij J, Wanders J, et al. Docetaxel: An active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995; 87:676-81.
11. Hoskins P J, Swenerton K D. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994; 12:60-3.
12. Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer. Gynecol Oncol 1997; 65:42-5.
13. Bajetta E, Di leo A, Biganzoli L, Mariani L, Cappuzzo F, Bartolomeo M D, et at. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1996; 14:2546-51.
14. Larusso V, Catino A, Leone B, Rabinovich M, Gargano G, Paradiso A, et al. Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study. J Clin Oncol 1993; 11:1952-6.
15. Omura G A, Bundy B N, Berek J S, Curry S, Delgado G, Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1989; 7:457-65.
16. Bertelsen K. Tumour reduction surgery and long-term survival in advanced ovarian cancer: A DACOVA Study. Gynecol Oncol 1990; 38:203-9.
17. Omura G A, Brady M F, Homesley H D, Jordan E, Major F J, Buchsbaum H J, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group Experience. J Clin Oncol 1991; 9:1138-50.
18. Rubin S C, Wong G Y C, Curtin J P, Barakat R R, Hakes T B, Hoskins W J. Platinum-based chemotherapy of high-risk stage I epithelial ovarian cancer following comprehensive surgical staging. Obstet Gynecol 1993; 82:143-7.
19. Shimizu Y, Umezawa S, Takeshima N, Hirai Y, Fujimoto I, Yamauchi K, et al. Chemotherapy of ovarian cancer patients with a combination of low-dose consecutive CDDP and cyclophosphamide. Acta Obstet Gynaecol Jpn 1993; 45:444-50.
20. Shimizu Y. Individualized chemotherapeutic regimen for each histological subtype of ovarian carcinoma. Jpn J Cancer Chemother 1997; 24(Supp II):241-9.
21. Sutton G P, Stehman F B, Einhorn L H, Roth L M, Blessing J A, Ehrlich C E. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 1989; 7:223-9.
22. Robey S. Silva E, Gershenson D, McLemore D, El-Nagger A, Ordonez N. Transitional cell carcinoma in high-grade high-stage ovarian carcinoma. An indicator of favorable response to chemotherapy. Cancer 1989; 63:839-49.
23. Gershenson D M, Silva E G, Michele M F, Atkinson E N, Wharton J T. Transitional cell carcinoma of the ovary: a matched control study of advanced-stage patients treated with cisplatin-based chemotherapy. Am J Obstet Gynecol 1993; 168:1178-87.
24. Jenison E L, Montag A G, Griffiths C T, Welch W R, Lavin P T, Greer J, et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989; 32:65-71.
25. Kennedy A W, Biscotti C V, Hart W R, Webster K D. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989; 32:342-9.
26. Kennedy A W, Biscotti C V, Hart W R, Tuason L J. Histologic correlates of progression-free interval and survival in ovarian clear cell adenocarcinoma. Gynecol Oncol 1993; 50:334-8.
27. Goff B A, De La Cuesta R S, Muntz H G, Fleischhacker D, Ek M, Rice L W, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996; 60:412-7.
28. Recio F O, Piver M S, Hempling R E, Driscoll D L. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 1996; 78:2157-63.
29. Schevchuk M M, Winkler-Monsanto B, Fenoglio C M, Richart R M. Clear cell carcinoma of the ovary: a clinicopathologic study with review of the literature. Cancer 1981; 47:1344-51.
30. Crozier M A, Copeland L J, Silva E G, Gershenson D M, Stringer C A. Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol 1989; 35:199-203.
31. Montag A G, Jenison E L, Griffiths C T, Welch W R, Lavin P T, Knapp R C. Ovarian clear cell carcinoma: a clinicopathologic analysis of 44 cases. Int J Gynecol Pathol 1989; 8:85-96.
32. Brescia R J, Dubin N, Demopulos R I. Endometrioid and clear cell carcinoma of the ovary: factors affecting survival. Int J Gynecol Pathol 1989; 8:132-8.
33. Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg S G. Toward the development of a universal grading system for ovarian epithelial carcinoma. Testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998; 82:893-901.
34. Shimizu Y, Nagata H, Umezawa S, Nishida M, Kikuchi Y, Hasumi K, et al. Activity of cytotoxic agents against clear cell carcinoma of the ovary which is intrinsically platinum-refractory. Oncol Rep 1997; 4:945-8.
35. Shimizu Y, Nagata H, Kikuchi Y, Umezawa S, Hasumi K, Yokokura T. Cytotoxic agents active against mucinous adenocarcinoma of the ovary. Oncol Rep 1998; 5:99-101.
36. World Health Organization. WHO/UICC Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva, Switzerland: WHO, 1979:14-27.
37. SAS Software. Cary, North Carolina: SAS Institute Inc, 1986.
38. Wilcoxon F. Individual comparison by ranking methods. Biometrics Bull 1945; 1:80-3.
39. Snedecor G W, Cochran W G. Statistical Methods. 7th ed. Ames: Iowa State Univ Press, 1980.
40. Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
41. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163-70.
42. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, et al. Effects of CPT-11 in combination with other anti-cancer. Int J Cancer 1992; 50:604-10.
43. Takeuchi S, Dobashi K, Fujimoto S, Tanaka K, Suzuki M, Terashima Y, et al. A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research groups of CPT-11 in gynecologic cancers. Gan To Kagakuryoho 1991; 18:1681-9.
44. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, et al. CPT-11 gastrointestinal cancer study group. Phase II study of CPT-11, a new camptothecin derivative in metastatic colorectal cancer. J Clin Oncol 1993; 11:909-13.
45. de Forni M, Bugat R, Chabot G G, Culine S, Extra J M, Gouyette A, et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 1994; 54:4347-54.
46. Verschraegen C F, Levy T, Kudelka A P, Lierena E, Ende K, Freedman R S, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997; 15:625-31.
47. Ohe Y, Sasaki Y, Shinkai T, Eguchi K, Tamura T, Kojima A, et al. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 1992; 84:972-4.
48. Houghton P J, Cheshire P J, Hallman J C, Bissery M C, Mathieu-Boue A, et al. Therapeutic efficacy lacy of the toposiomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumour xenografts: Lack of cross-resistance in vivo in tumours with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 1993; 28:2823-9.
49. Furuta T, Yokokura T. Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative. Gan To Kagaku Ryoho 1990; 17:121-30.
50. Bissery M C, Vrignaud P, Lavelle F, Chabot G G. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs 1996; 7:437-60.
51. Shimizu Y. Pharmacokinetics of consecutive low-dose cisplatin. Oncol Rep 1997; 4:591-3.
52. Shimizu Y, Akiyama F, Umezawa S, Ishiya T, Utsugi K, Hasumi K. Combination of consecutive low-dose cisplatin with bleomycin, vincristine, and mitomycin for recurrent cervical carcinoma. J Clin Oncol 1998; 16:1869-78.